Long-term survival with anti-PD-1-based immunotherapy, but what is the best approach?
Mené sur 945 patients atteints d'un mélanome de stade avancé (stade III ou IV), présentant la mutation BRAF V600 et non résécable, cet essai de phase III compare l'efficacité, du point de vue de la survie sans progression et de la survie globale, et la toxicité du nivolumab en monothérapie, de l'ipilimumab en monothérapie, et d'un traitement combinant nivolumab et ipilimumab (durée médiane de suivi : 47 mois)
Checkpoint inhibitor immunotherapy has transformed the treatment of melanoma in the past 7 years, and can even lead to durable long-term survival outcomes in some patients with metastatic disease. However, we still have much to learn about how best to use these drugs and how to mitigate their side-effects. The optimal combination regimens, treatment duration, patient selection, and the point in the disease trajectory at which immunotherapy can be deployed to best effect remain open questions.
The Lancet Oncology , commentaire, 2017